ThromboGenics and BioInvent Start Phase II Trial of TB-402, an Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
Trial to assess the benefits of partial Factor VIII inhibition in patients undergoing knee replacement surgery
Advertisement
ThromboGenics NV and co-development partner BioInvent International announce that the first patient has been enrolled in the Phase II trial with their long-acting anticoagulant TB-402 for the prophylaxis of deep vein thrombosis (DVT) following orthopaedic surgery. TB-402, which is given as a single injection post surgery, could overcome the major drawbacks such as bleeding and the need for extensive patient monitoring associated with current anti-coagulant therapy.
TB-402 is a recombinant human monoclonal antibody that targets Factor VIII, a key component of the coagulation cascade. TB-402 is a novel anticoagulant agent, which may deliver important clinical benefits due to it only partially inhibiting Factor VIII activity even when given in very high doses. This novel mode of action is expected to reduce the risk of undesirable bleeding events and the need for patient monitoring, the two main drawbacks associated with current anticoagulants. In addition, TB-402 is a long-acting agent which means that patients are expected to receive just one single dose after surgery to prevent the development of DVT, as opposed to all current treatment options which require daily treatment for up to several weeks.
The Phase II trial is an active (enoxaparin)-controlled, dose-escalating, multicenter, prospective, randomised, open label trial evaluating TB-402 for the prophylaxis of DVT after knee surgery. The study will assess three different doses of TB-402 given as a single intravenous bolus injection post knee replacement surgery. The trial will enrol 300 patients across 36 centers mainly in Central Europe. The primary endpoint is the safety and efficacy of the three escalating doses of TB-402. It is anticipated that the study will conclude by the end of 2010.
Other news from the department research and development
Most read news
More news from our other portals
Last viewed contents
Genzyme and Project HOPE Partner to Rebuild Critical Health Care Programs in Tsunami-Affected Areas
ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study with Anti-Factor VIII (TB-402)
Evotec expands Oxfordshire site into a fully-integrated R&D centre - "Dorothy Crowfoot Hodgkin Campus"
From cancer medication to antibiotic - Modified cancer drug effective against multi-resistant bacteria
Lyme disease: Probability of developing the disease is genetically predisposed - Research team discovers gene variant and genes involved in immune regulation that are responsible for the outbreak of Lyme disease
Sarcospan, a little protein for a big problem
Insects as mini molecule-making factories, marking a breakthrough in chemical engineering - Caterpillar factories produce fluorescent nanocarbons
Key molecular interactions of the ZMapp anti-Ebola virus cocktail identified
Strüngmann Award Honors Araris Biotech Founding Team as 2025 Winner - The founding team is developing a breakthrough technology to establish a new generation of targeted cancer therapies
Upcoming ECHA notification deadlines
Caprotec bioanalytics appoints Prof. Dr. Metternich as Managing Director, Chief Business Officer and Chief Operating Officer
